5Y Capital
5Y Capital is a private equity and venture capital firm based in Shanghai, China, specializing in seed, startup, early venture, and growth capital investments. Established in 1992, the firm focuses on a diverse range of sectors, including healthcare, technology, fintech, internet services, consumer services, media, and life sciences, among others. It aims to support entrepreneurs in building innovative companies, particularly in China and other emerging markets in Asia/Pacific. Managing approximately USD 5 billion in dual-currency funds, 5Y Capital attracts investments from global sources, including sovereign wealth funds and family offices. The firm typically makes initial investments exceeding USD 500,000 per portfolio company. 5Y Capital operates under the Morningside Group, which is committed to socially responsible investing, particularly in educational opportunities and scientific research.
GreenLight Biosciences is a biotechnology company that specializes in RNA-based solutions for agricultural and pharmaceutical applications. Founded in 2008 and headquartered in Medford, Massachusetts, with an additional location in North Carolina, the company utilizes its Unconstrained Metabolism technology platform to convert renewable substrates into valuable chemicals and fuels. This platform allows for significant flexibility and control in the production process. GreenLight is also focused on developing RNA products aimed at improving crop management, plant protection, and animal health, while advancing vaccine development and pandemic preparedness. In addition to these applications, the company is working on mRNA-based vaccine candidates targeting seasonal and pandemic influenza, as well as other emerging viruses, to enhance public health. Through its innovations, GreenLight aims to provide sustainable solutions that contribute to global food security and health.
Liquidia Technologies is a late-stage clinical biopharmaceutical company based in Morrisville, North Carolina, that specializes in the development and commercialization of human therapeutics. The company utilizes its proprietary PRINT technology, a particle engineering platform that allows for the precise production of uniform drug particles, aimed at improving the safety, efficacy, and performance of various therapies. Liquidia is currently advancing two key product candidates: LIQ861 for the treatment of pulmonary arterial hypertension and LIQ865 for addressing local post-operative pain. In addition to its internal pipeline, Liquidia collaborates with leading pharmaceutical companies to leverage its PRINT technology across multiple therapeutic areas and drug types. The company also offers strategy and commercialization services for rare disease pharmaceutical products, including a generic formulation of treprostinil for pulmonary arterial hypertension. Founded in 2004, Liquidia Technologies continues to focus on transforming patient care through innovative therapeutic solutions.
Argos Therapeutics, Inc., a biotechnology company, engages in developing immunotherapy treatments for cancer, infectious and autoimmune diseases, and transplantation rejection. The company has clinical trial programs in cancer and human immunodeficiency virus. Its products include AGS-0031 for metastatic renal cell carcinoma; AGS-0041 for HIV; CD83 soluble protein for transplant rejection/autoimmune disorders; Anti IFN-alpha monoclonal antibody2 for lupus; and regulatory T cell therapy3 for autoimmune disorders. The company was formerly known as MERIX Bioscience, Inc. Argos Therapeutics was founded in 1997 and is based in Durham, North Carolina.
Envisia Therapeutics Inc. is a biotechnology company dedicated to discovering and developing innovative therapies for ocular conditions. Founded in 2013 and based in Durham, North Carolina, the company addresses significant unmet medical needs in ophthalmology, particularly for conditions like glaucoma. Envisia's lead product, ENV515, is a prostaglandin analogue formulated with a biodegradable PRINT particle technology, designed to provide sustained intraocular pressure reduction over several months. The company's research and development efforts focus on overcoming barriers associated with traditional ocular therapies, such as poor drug uptake and systemic side effects, by utilizing biocompatible polymers and extended-release delivery systems. With an increasing demand for effective ocular therapeutics due to a rapidly aging population, Envisia aims to significantly improve patient outcomes and adherence to treatment protocols in the field of eye care.
Chimerix, Inc. is a biopharmaceutical company based in Durham, North Carolina, dedicated to developing innovative antiviral therapeutics for patients with serious diseases, including cancer and those undergoing transplant procedures. The company’s lead candidate, CMX001, targets life-threatening double-stranded DNA viral infections and has demonstrated antiviral activity in clinical studies involving immunocompromised patients. Ongoing research includes a Phase 2 study for preventing cytomegalovirus in stem cell transplant recipients and other studies addressing adenovirus and various herpes viruses. Chimerix is also developing CMX157, a nucleoside analogue aimed at treating HIV and hepatitis B, which has shown promising results in early trials. Additionally, the company is working on dociparstat sodium, a compound intended to inhibit key proteins linked to acute myeloid leukemia, and brincidofovir, an antiviral candidate for smallpox. Chimerix holds various licensing agreements to advance its research and has received substantial federal funding to support its initiatives in public health and medical countermeasures.
Liquidia Technologies is a late-stage clinical biopharmaceutical company based in Morrisville, North Carolina, that specializes in the development and commercialization of human therapeutics. The company utilizes its proprietary PRINT technology, a particle engineering platform that allows for the precise production of uniform drug particles, aimed at improving the safety, efficacy, and performance of various therapies. Liquidia is currently advancing two key product candidates: LIQ861 for the treatment of pulmonary arterial hypertension and LIQ865 for addressing local post-operative pain. In addition to its internal pipeline, Liquidia collaborates with leading pharmaceutical companies to leverage its PRINT technology across multiple therapeutic areas and drug types. The company also offers strategy and commercialization services for rare disease pharmaceutical products, including a generic formulation of treprostinil for pulmonary arterial hypertension. Founded in 2004, Liquidia Technologies continues to focus on transforming patient care through innovative therapeutic solutions.
Liquidia Technologies is a late-stage clinical biopharmaceutical company based in Morrisville, North Carolina, that specializes in the development and commercialization of human therapeutics. The company utilizes its proprietary PRINT technology, a particle engineering platform that allows for the precise production of uniform drug particles, aimed at improving the safety, efficacy, and performance of various therapies. Liquidia is currently advancing two key product candidates: LIQ861 for the treatment of pulmonary arterial hypertension and LIQ865 for addressing local post-operative pain. In addition to its internal pipeline, Liquidia collaborates with leading pharmaceutical companies to leverage its PRINT technology across multiple therapeutic areas and drug types. The company also offers strategy and commercialization services for rare disease pharmaceutical products, including a generic formulation of treprostinil for pulmonary arterial hypertension. Founded in 2004, Liquidia Technologies continues to focus on transforming patient care through innovative therapeutic solutions.